GLPGF News and Press, Galapagos Genomics Ord From 01/05/21

The world is awash with liquidity as interest rates remain at historic lows. Cheap liquidity is the fuel that will spark the next buyout bing in smaller cap biotech. A diversified ETF specializing in smaller cap biotechs is the perfect vehicle to capitalize on the trend as detaile...

Due to the FDA's rejection of Filgotinib's 200 mg dosage for commercialisation in the US. Galapagos' earnings potential has been hampered severely. Yet, the current net cash position exceeds the company's market capitalization. The pipeline has multiple potentially blockbuster mol...

Galapagos NV (GLPG) Q3 2020 Results Conference Call November 06, 2020 08:00 AM ET Company Participants Elizabeth Goodwin - Investor Relations Onno van de Stolpe - Chief Executive Officer Andre Hoekema - Chief Business Officer Bart Filius - Chief Operating and Financial Officer Walid Abi-Saab ...

The following slide deck was published by Galapagos NV in conjunction with their 2020 Q3 earnings call. For further details see: Galapagos NV 2020 Q3 - Results - Earnings Call Presentation

GILD reports earnings after-hours. Remdesivir could revive growth in the short term. However, revenue from HIV and HCV could be dead for now. GLPG's R&D pipeline has suffered some setbacks and may not be the boon GILD once thought. The IMMU deal could limit GILD's ability ...

Galecto has filed proposed terms for an $85 million U.S. IPO. The firm is development treatments for various fibrosis diseases. GLTO has produced impressive trial results to-date. For life science investors with a long-term hold time frame, the IPO is worth considering. ...

Galapagos announces topline data from knee osteoarthritis trial. Evelo provides updates for EDP1815 in Atopic Dermatitis and Psoriasis trials. CTI BioPharma initiates NDA process for Pacritinib. For further details see: Galapagos Knee Osteoarthritis Data, And Other News:...

The following slide deck was published by Galapagos NV in conjunction with this event. For further details see: Galapagos ADR (GLPG) Investor Presentation - Slideshow

Amyris Inc. suffers a setback over patent lawsuit Amyris Inc. ( AMRS ) has been hit by a patent lawsuit instituted by Lavvan Inc. The $881 million lawsuit has been filed in the United States District Court for the Southern District of New York. Both the companies had inked a Research, Coll...

G1 Therapeutics receives FDA acceptance of its Small Cell Lung Cancer NDA G1 Therapeutics Inc. ( GTHX ) reported that the FDA has accepted its New Drug Application of its lead drug candidate, Trilaciclib. The FDA has given Priority Review status to the NDA, and the PDUFA action date has ...